JP2007326858A - 泌尿系感染の予防又は治療に使用される組成物 - Google Patents
泌尿系感染の予防又は治療に使用される組成物 Download PDFInfo
- Publication number
- JP2007326858A JP2007326858A JP2007152032A JP2007152032A JP2007326858A JP 2007326858 A JP2007326858 A JP 2007326858A JP 2007152032 A JP2007152032 A JP 2007152032A JP 2007152032 A JP2007152032 A JP 2007152032A JP 2007326858 A JP2007326858 A JP 2007326858A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- matrix metalloproteinase
- composition according
- urinary
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000002485 urinary effect Effects 0.000 title claims abstract description 15
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 4
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims abstract description 28
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims abstract description 28
- 208000019206 urinary tract infection Diseases 0.000 claims description 41
- 210000002700 urine Anatomy 0.000 claims description 31
- 244000052769 pathogen Species 0.000 claims description 23
- 210000002540 macrophage Anatomy 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 239000003381 stabilizer Substances 0.000 claims description 9
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000003352 sequestering agent Substances 0.000 claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 244000000010 microbial pathogen Species 0.000 claims description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 4
- 102000004631 Calcineurin Human genes 0.000 claims description 4
- 108010042955 Calcineurin Proteins 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical group OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 4
- 240000001949 Taraxacum officinale Species 0.000 claims description 4
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 240000004153 Hibiscus sabdariffa Species 0.000 claims description 3
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 claims description 3
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 3
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 3
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 241000252229 Carassius auratus Species 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 2
- 229920002079 Ellagic acid Polymers 0.000 claims description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 2
- 241000221079 Euphorbia <genus> Species 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000016554 Rubus chamaemorus Nutrition 0.000 claims description 2
- 240000006831 Rubus chamaemorus Species 0.000 claims description 2
- 240000007651 Rubus glaucus Species 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 2
- 240000002657 Thymus vulgaris Species 0.000 claims description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 2
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229960002852 ellagic acid Drugs 0.000 claims description 2
- 235000004132 ellagic acid Nutrition 0.000 claims description 2
- 235000004515 gallic acid Nutrition 0.000 claims description 2
- 229940074391 gallic acid Drugs 0.000 claims description 2
- 229960004275 glycolic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 2
- 239000010813 municipal solid waste Substances 0.000 claims description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000001585 thymus vulgaris Substances 0.000 claims description 2
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 claims description 2
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 claims description 2
- 240000002853 Nelumbo nucifera Species 0.000 claims 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 2
- 235000007173 Abies balsamea Nutrition 0.000 claims 1
- 241000205585 Aquilegia canadensis Species 0.000 claims 1
- 239000004857 Balsam Substances 0.000 claims 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims 1
- 235000017491 Bambusa tulda Nutrition 0.000 claims 1
- 240000007124 Brassica oleracea Species 0.000 claims 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims 1
- 241000219357 Cactaceae Species 0.000 claims 1
- 235000005940 Centaurea cyanus Nutrition 0.000 claims 1
- 240000004385 Centaurea cyanus Species 0.000 claims 1
- 235000005979 Citrus limon Nutrition 0.000 claims 1
- 244000131522 Citrus pyriformis Species 0.000 claims 1
- 241000208296 Datura Species 0.000 claims 1
- 244000004281 Eucalyptus maculata Species 0.000 claims 1
- 235000016623 Fragaria vesca Nutrition 0.000 claims 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 claims 1
- 244000018716 Impatiens biflora Species 0.000 claims 1
- 235000006770 Malva sylvestris Nutrition 0.000 claims 1
- 240000002129 Malva sylvestris Species 0.000 claims 1
- 241000258241 Mantis Species 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 241000238633 Odonata Species 0.000 claims 1
- 235000000771 Opuntia streptacantha Nutrition 0.000 claims 1
- 244000221569 Opuntia streptacantha Species 0.000 claims 1
- 240000004371 Panax ginseng Species 0.000 claims 1
- 235000002789 Panax ginseng Nutrition 0.000 claims 1
- 241000269979 Paralichthys olivaceus Species 0.000 claims 1
- 244000082204 Phyllostachys viridis Species 0.000 claims 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims 1
- 235000011034 Rubus glaucus Nutrition 0.000 claims 1
- 235000009122 Rubus idaeus Nutrition 0.000 claims 1
- 241001404789 Smilax glabra Species 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 claims 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000011425 bamboo Substances 0.000 claims 1
- 239000008989 cinnamomi cortex Substances 0.000 claims 1
- 235000004634 cranberry Nutrition 0.000 claims 1
- 235000008434 ginseng Nutrition 0.000 claims 1
- 235000002532 grape seed extract Nutrition 0.000 claims 1
- 229940087603 grape seed extract Drugs 0.000 claims 1
- 229910052602 gypsum Inorganic materials 0.000 claims 1
- 239000010440 gypsum Substances 0.000 claims 1
- 244000138993 panchioli Species 0.000 claims 1
- 239000001717 vitis vinifera seed extract Substances 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 abstract description 10
- 230000027939 micturition Effects 0.000 abstract description 8
- 230000007123 defense Effects 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 108060003393 Granulin Proteins 0.000 abstract description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 19
- 239000003826 tablet Substances 0.000 description 18
- 210000001635 urinary tract Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000008187 granular material Substances 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 10
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 210000003097 mucus Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 208000006750 hematuria Diseases 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- ZROGCCBNZBKLEL-FHXNIQKESA-N Astilbin Natural products O([C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZROGCCBNZBKLEL-FHXNIQKESA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 108010026132 Gelatinases Proteins 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 208000037581 Persistent Infection Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- ZROGCCBNZBKLEL-MPRHSVQHSA-N astilbin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1 ZROGCCBNZBKLEL-MPRHSVQHSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 4
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 208000000143 urethritis Diseases 0.000 description 4
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 3
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 206010037596 Pyelonephritis Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940074393 chlorogenic acid Drugs 0.000 description 3
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 3
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 3
- 235000001368 chlorogenic acid Nutrition 0.000 description 3
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000003146 cystitis Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000004503 fine granule Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- 206010056396 Asymptomatic bacteriuria Diseases 0.000 description 2
- 201000004538 Bacteriuria Diseases 0.000 description 2
- 101150013553 CD40 gene Proteins 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 102100027995 Collagenase 3 Human genes 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241001495410 Enterococcus sp. Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 240000000691 Houttuynia cordata Species 0.000 description 2
- 235000013719 Houttuynia cordata Nutrition 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 2
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 241000490567 Pinctada Species 0.000 description 2
- 241000334216 Proteus sp. Species 0.000 description 2
- 208000008718 Pyuria Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 235000021019 cranberries Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229920001968 ellagitannin Polymers 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 2
- 210000003622 mature neutrocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OFCWIPGKPUJTDP-CFVMTHIKSA-N (2s,3r)-n-hydroxy-2-methyl-n'-[(1s)-2-(methylamino)-2-oxo-1-phenylethyl]-3-(2-methylpropyl)butanediamide Chemical compound ONC(=O)[C@@H](C)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NC)C1=CC=CC=C1 OFCWIPGKPUJTDP-CFVMTHIKSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000052707 Camellia sinensis Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000309023 Cynara scolymus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- KDHHWXGBNUCREU-HOTGVXAUSA-N Ferric-aerobactin Chemical compound CC(=O)N(O)CCCC[C@@H](C(O)=O)NC(=O)CC(O)(C(O)=O)CC(=O)N[C@H](C(O)=O)CCCCN(O)C(C)=O KDHHWXGBNUCREU-HOTGVXAUSA-N 0.000 description 1
- 208000002513 Flank pain Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 241000511338 Haliaeetus leucocephalus Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 108700010340 Leishmanolysins Proteins 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 241001570521 Lonicera periclymenum Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000036436 Metzincins Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000123725 Sophora tonkinensis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- JXAGDPXECXQWBC-LJQANCHMSA-N Tanomastat Chemical compound C([C@H](C(=O)O)CC(=O)C=1C=CC(=CC=1)C=1C=CC(Cl)=CC=1)SC1=CC=CC=C1 JXAGDPXECXQWBC-LJQANCHMSA-N 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010000196 Urinary abnormalities Diseases 0.000 description 1
- 102000018614 Uromodulin Human genes 0.000 description 1
- 108010027007 Uromodulin Proteins 0.000 description 1
- 206010048709 Urosepsis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000001224 bacterial fimbriae Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 235000020237 cranberry extract Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- -1 etc.) Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108010008385 glycolipid receptor Proteins 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 235000021013 raspberries Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 208000024470 urgency of urination Diseases 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】本発明は、マトリックスメタロプロテイナーゼインヒビターを活性成分として含有する泌尿系感染の予防又は治療に使用される組成物に関する。この組成物は、主にマトリックスメタロプロテイナーゼインヒビターを利用して、ライニング粘膜のマトリックスタンパクの分解と炎症反応の拡散を阻害することにより、膀胱と泌尿管内を覆うライニンググリコサミノグリカンの完全性を保護し、正常な防御機能を発揮させる。
【選択図】なし
Description
(1)接種菌量(inoculum size)と尿路における細菌の滞留時間;
(2) 微生物が症状を引起こす菌力(ビルレンス);
(3) ホスト自己防衛メカニズムの受容能力。
(1)マトリックスメタロプロテイナーゼインヒビターを介して、活性細胞の遊走を抑え、炎症反応の拡散をコントロール(抑制)すると同時に、ライニング粘液のマトリックスタンパク質の分解を抑制し、これにより膀胱、尿路内を覆うライニング粘液のグリコサミノグルカンの完全性を維持する。
(2)マクロファージ機能変調剤を介して免疫機能をコントロールし、食菌作用を増強し、発熱物質の分泌を抑制する。
(3)微生物病原体の隔離剤を介して病原体を隔離し、病原体の排除を増強する。
(4)尿液のpH安定剤を介して、尿液を弱酸性に安定させ、病原体の増殖を軽減する。
前立腺炎(prostatitis)、副睾丸炎(epididymitis)腎于腎炎(pyelonephritis)、無症候細菌尿(asymptomatic bacteriuria)、症候性泌尿系感染(symptomatic urinary system infection)、細菌尿(bacteriuria)、血尿(hematuria)、肉眼的血尿(hemuresis)、膿尿(pyuria)と尿性敗血症(urosepsis)など(しかし、これらに限定されない)の泌尿系感染に利用される。通常、泌尿系感染をもたらす病原体としては、大腸菌(E. coli)、プロテウス・ミラビリス(Proteus mirabilis)、クレブシェラ・ニューモニエ(Klebsiella pneumoniae)、緑膿菌(Pseudomonas aeruginosa)、クラミジア(Chlamydia)、マイコプラズマ(Mycoplasm)、スタヒロコッカス・サプロフィティカス(Staphylococcus saprophyticus)、プロテウス菌(Proteus sp.)、エンテロコッカス菌(Enterococcus sp.)と表皮ブドウ球菌(Staphylococcus epidermidis)などからなる微生物より選ばれる一種又は一種以上の病原菌が挙げられ、特に、大腸菌は泌尿系感染の主な病原体である。
本発明の多面性と特性を示す典型的な実施例を以下に示すが、本発明はこれら実施例に限定されるものではない。
泌尿系感染の予防又は治療に使用される組成物を調製するため、活性成分と製薬学上許容される賦形剤(例えば、乳糖、ソルビトール、マンニトール、ステアリン酸マグネシウムなど)とを調合する。上記活性成分として、アスチルビン(Astilbin)抽出物130mg/錠(又は細粒剤)を用いる。
泌尿系感染の予防又は治療に使用される組成物を調製するため、活性成分と製薬学上許容される賦形剤(例えば、乳糖、ソルビトール、マンニトールとステアリン酸マグネシウムなど)とを調合する。上記活性成分として、アスチルビン(Astilbin)抽出物130mg/錠(又は細粒剤)と、クロロゲン酸(Chlorogenic acid)抽出物60 mg/錠(又は細粒剤)を用いる。
泌尿系感染の予防又は治療に使用される組成物を調製するため、活性成分と製薬学上許容される賦形剤(例えば、乳糖、ソルビトール、マンニトールとステアリン酸マグネシウムなど)とを調合する。上記活性成分として、クランベリー抽出物150mg/錠(又は細粒剤)、ビタミンC 70mg/錠(又は細粒剤)、アスチルビン(Astilbin)抽出物130mg/錠(又は細粒剤)とクロロゲン酸(Chlorogenic acid)抽出物60 mg/錠(又は細粒剤)とを用いる。
(1) 症状の軽減による評価
尿道下部感染症状による評価、排尿困難(dysuira)、急尿(urgency of urination)、頻尿(frequency of urination)、夜間多尿症(nocturia)、血尿(hemuresis)と恥骨上沈重感(suprapubic heaviness)が含まれる。
尿道上部感染症状による評価、側腹痛(abdominal flank pain)、発熱(fever)、悪心(nausea)、嘔吐(vomiting)と不快感(malaise)が含まれる。
尿中の白血球含量の劇的降下、尿中の沈澱物の明らかな減少、尿タンパクの改進や消失、尿液培養物が病原体の含有に陰性反応を示すなどとその他が含まれる。
血尿症状を示し、排尿時に灼熱的刺痛感を伴う44才の女性看護士を試験対象とする。その尿路感染は十分に明らかであり、例えば、下腹に重圧感を訴え、頻尿、急尿、排尿困難などの症状が見られる。過去における患者の泌尿科での診断から再発性尿路感染と診断された。医療検査を行う前に、製造例3の組成物を5時間内に2回服用し、第2回目の服用時から2時間後に、尿路感染症状は明らかに軽減した。その後、病院に行かず製造例3の組成物を3日持続して服用した結果、すべての尿路感染症状は消失した。
泌尿科で尿路感染と診断され、尿液培養による検査でも白血球含量が高すぎ、且つ2種類の異なる病原菌が感染した閉経期の女性を対象として試験を行った。先に、第一線の抗生物質であるセファロスポリンを用い一週間治療しても、白血球含量は持続して高過ぎる値を示し、更に、抗生物質に替わりサルファ剤で一週間治療しても、白血球含量はやはり持続して高い結果を示した。
その後、この患者に製造例3の組成物を毎日3回服用するよう勧めたところ、服用後一週間後にすべての尿路感染症状が消えさり、白血球含量も正常に回復した。
意識不明で且つ鼻胃管と導尿管を挿入している79才の卒中女性患者が、再発性尿路感染をおこし、持続して長い時間発熱した。血尿と膿尿の症状から、尿液は混濁し悪臭を伴い、導尿管内にも多くの結晶が沈澱するのがみられた。このような患者に製造例3の組成物を毎日3回服用したところ、一週間後に尿液と導尿管の清澄度が明らかに改善され、強い悪臭も消え、発熱も治まった。
慢性又は再発性尿路感染患者13名について試験を行った。製造例3の組成物を1回1錠、毎日3回服用させ、2週間から3ヶ月にわたり服用を続けた。患者12名中の11名(91.7%)に、尿液沈澱物の混濁状態から曇り状態又は清澄状態になって尿液混濁を軽減したのがみられ、又、尿液のOD値による評価でも混濁から清澄になって、症状に軽減したことが示された。
75%(9/12名)の患者において尿中のWBC値が明らかに低減するのが示された。
87.5%(7/8名)の患者の尿タンパク症状が消失又は軽減した。
46%(6/13名)の患者が尿液細胞培養により、尿液の病原体が陰性を示した。
本実験は2組に分けて行われた。第1組は、ただバクターサルファ剤(サルファメトキサゾール+トリメトプリム)を3日服用したものであり、第2組は、製造例3の組成物を7日間服用したものである。第3日目に症状の改善について評価した結果、第1組においては、22の病例中、症状が完全に消失(UTISA症状の評価値=0)のは2例にとどまり、第2組においては、21の病例中、7例の症状が完全に消失した。これらは、最初の平均的症状における第2組の評価が第1組に比べて高い(20.1±10.4対15.0±6.3、P=0.056)のにも係わらず、第2組の結果が如何に良いかを示すものである。
この外、第7日目に、臨床試験検査を行い、尿液の分析結果より、本発明の組成物を服用した第2組は第1組に比べて更に多くの完治した患者が見られ、第2組においては18病例中16例の治癒に対し、第1組では18病例中12例の治癒がそれぞれ示された。
Claims (12)
- マトリックスメタロプロテイナーゼインヒビターを活性成分として含有することを特徴とする泌尿系感染の予防又は治療に使用される組成物。
- 前記マトリックスメタロプロテイナーゼインヒビターが、MMP-2インヒビターとMMP-9インヒビターを含む群から選ばれるものであることを特徴とする請求項1に記載の組成物。
- 前記マトリックスメタロプロテイナーゼインヒビターが、ナツメ(Zizyphus jujuba)、ゼニアオイ(Malva sylvestris)、メキシコサボテン(Opuntia Streptacantha)、ニクケイ(Cinnamomi Cortex)、グミ(Hippophae rhamnoides)、オタネニンジン(Panax ginseng)、ビワ(Eriobotrya japonica)、台湾ヒラミレモン(シイクワシヤー,Citus depressa Hayata)、ハス(Nelumbo nucifera)、ホソバヤマジソ(Mosla chinensis)、ゴミシ(Fructus schizandrae)、ダルベギア(Dalbergia odorfera)、カラサンキライ(Smilax glabra)、及びケール(kale)の抽出物からなる群より選ばれるものであることを特徴とする請求項1に記載の組成物。
- マトリックスメタロプロテイナーゼインヒビターとマクロファージ機能変調剤を含有することを特徴とする泌尿系感染の予防又は治療に使用される組成物。
- マトリックスメタロプロテイナーゼインヒビターとマクロファージ機能変調剤との比率が、重量当り、10:1〜1:5の範囲内にあることを特徴とする請求項4に記載の組成物。
- 前記マクロファージ機能変調剤が、カルシニューリン酵素の活性化が可能であることを特徴とする請求項4に記載の組成物。
- 前記マクロファージ機能変調剤が、スイカズラ、トウチュウカソウ、トウクララ、グミ、キンギンカ、ハクトウオウ、茶葉、マンネンタケ、アマチャヅル、チョウセンアザミ、タイム、ゴミシ、ウツボグサ、トウキ、トウオウレン、セイヨウタンポポ、バシケン、サンシシ、サンズコン、ドクダミ、レンギョウ、サンキライ、及びオウレンの抽出物からなる群より選出ばれるものであることを特徴とする請求項4に記載の組成物。
- マトリックスメタロプロテイナーゼインヒビター、マクロファージ機能変調剤、微生物病原体の隔離剤と尿液pH安定剤を含有することを特徴とする泌尿系感染の予防又は治療に使用される組成物。
- 前記マトリックスメタロプロテイナーゼインヒビターとマクロファージ機能変調剤との比率が、重量当り、10:1〜1:5の範囲内にあることを特徴とする請求項8に記載の組成物。
- 病原体隔離剤が、クランベリー、クラウドベリー、ラズベリー、イチゴ、ビルベリー、グミ、ブドウ、ローゼル及びブドウ種子の抽出物からなる群より選ばれるものであることを特徴とする請求項8に記載の組成物。
- 前記尿液pH安定剤が、グリコール酸、没食子酸、エラグ酸、バニリン酸、クエン酸、リンゴ酸、酒石酸、乳酸とビタミンCからなる群より選ばれるものであることを特徴とする請求項8に記載の組成物。
- 請求項1、4、及び8のいずれか1項に記載の組成物を含有することを特徴とする泌尿系感染の予防又は治療に使用される医薬製剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/422,924 | 2006-06-08 | ||
US11/422,924 US8153166B2 (en) | 2006-06-08 | 2006-06-08 | Composition for prophylaxis or treatment of urinary system infection and method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007326858A true JP2007326858A (ja) | 2007-12-20 |
JP4786598B2 JP4786598B2 (ja) | 2011-10-05 |
Family
ID=38462228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007152032A Active JP4786598B2 (ja) | 2006-06-08 | 2007-06-07 | 泌尿系感染の予防又は治療に使用される組成物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8153166B2 (ja) |
EP (1) | EP1880719A3 (ja) |
JP (1) | JP4786598B2 (ja) |
CN (2) | CN101670004B (ja) |
AU (1) | AU2007202584B2 (ja) |
CA (1) | CA2590995C (ja) |
HK (2) | HK1111889A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019188491A1 (ja) * | 2018-03-29 | 2019-10-03 | 森永乳業株式会社 | 抗老化用組成物 |
JP2021512855A (ja) * | 2018-02-05 | 2021-05-20 | ヴェットケアー オイ | ラクトバシラスを含む健康に有益な組成物及びその調製方法 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8153166B2 (en) | 2006-06-08 | 2012-04-10 | Chih-Hsiung Lin | Composition for prophylaxis or treatment of urinary system infection and method thereof |
MX2007006334A (es) * | 2007-05-28 | 2009-02-18 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias. |
CN101868472B (zh) | 2007-11-21 | 2013-05-29 | 尔察祯有限公司 | 抗菌性氨基糖苷类似物 |
CN102481306A (zh) * | 2009-05-14 | 2012-05-30 | 尔察祯有限公司 | 使用抗菌氨基糖苷化合物治疗尿路感染 |
WO2010132768A1 (en) | 2009-05-15 | 2010-11-18 | Achaogen, Inc. | Antibacterial derivatives of sisomicin |
WO2010132759A1 (en) | 2009-05-15 | 2010-11-18 | Achaogen, Inc. | Antibacterial derivatives of dibekacin |
WO2010132765A2 (en) | 2009-05-15 | 2010-11-18 | Achaogen, Inc. | Antibacterial aminoglycoside analogs |
WO2010132760A1 (en) | 2009-05-15 | 2010-11-18 | Achaogen, Inc. | Antibacterial derivatives of tobramycin |
WO2010140832A2 (ko) * | 2009-06-04 | 2010-12-09 | 안국약품 주식회사 | 생약 추출물을 함유하는 신장염 질환 예방 또는 치료용 약학 조성물 |
CN102349655A (zh) * | 2011-10-14 | 2012-02-15 | 李泼 | 胶原蛋白多酚冲剂 |
CN102688305B (zh) * | 2012-06-11 | 2013-12-25 | 殷中琼 | 一种防治畜禽大肠杆菌病的中药制剂及其制备方法和应用 |
EP3037099A4 (en) * | 2013-08-21 | 2017-04-19 | Sichuan Jiuzhang Biological Science And Technology Co., Ltd | Pharmaceutical composition, preparation method therefor and use thereof |
KR20230004886A (ko) * | 2013-11-11 | 2023-01-06 | 나투렉스 인코포레이티드 | 하부 요로 증상, 양성 전립선 비대증, 발기부전 치료에 유용한 조성물 및 방법 |
CN105250280B (zh) | 2014-07-14 | 2020-03-10 | 诺维科国际控股股份有限公司 | 包含辛苯聚醇和喹诺里西啶生物碱化合物或其来源的杀微生物组合物 |
US9662367B2 (en) | 2014-08-01 | 2017-05-30 | Rubikon Ltd. | Adaptogenic compositions and method for production thereof |
EP3242680B1 (en) * | 2015-01-08 | 2021-10-13 | Selectimmune Pharma AB | Interleukin-1 receptor antagonist for use in the treatment of cystitis |
CN105535929A (zh) * | 2016-01-25 | 2016-05-04 | 张顺涛 | 一种护理治疗膀胱炎的药物组合物 |
EP3320897A1 (en) * | 2016-11-14 | 2018-05-16 | Dompè Primary S.r.l | Process for the preparation of coated cranberry granules with stable proanthocyanidine content |
EP3557249A4 (en) * | 2016-12-19 | 2020-09-30 | Yukashikado Inc. | URINE TESTING DEVICE AND URINE TESTING PROCEDURE |
US20180353174A1 (en) * | 2017-06-13 | 2018-12-13 | Ethicon Llc | Surgical Stapler with Controlled Healing |
US10939911B2 (en) | 2017-06-13 | 2021-03-09 | Ethicon Llc | Surgical stapler with end effector coating |
US11058804B2 (en) | 2017-06-13 | 2021-07-13 | Ethicon Llc | Surgical fastener device for the prevention of ECM degradation |
CN108042663B (zh) * | 2017-12-28 | 2021-01-22 | 宝健(北京)生物技术有限公司 | 一种美白祛斑且预防泌尿系统感染的组合物及其制备方法和应用 |
CN109106806A (zh) * | 2018-06-20 | 2019-01-01 | 广州宏韵医药科技股份有限公司 | 一种女性私密护理洗液及其制备方法 |
AU2020288361A1 (en) * | 2019-06-07 | 2022-02-03 | Selectimmune Pharma Ab | Treatment and diagnosis of chronic inflammatory conditions in the lower urinary tract |
CN110226593A (zh) * | 2019-07-30 | 2019-09-13 | 葛亮 | 一种生物组织冷冻保护液 |
CN111234322B (zh) * | 2020-02-17 | 2021-11-05 | 天津大学 | 一种高抗氧化性可食用包装薄膜及其制备方法 |
US11266707B2 (en) * | 2020-05-04 | 2022-03-08 | Therapeutic Solutions International, Inc. | Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19 |
GB202201139D0 (en) * | 2022-01-28 | 2022-03-16 | Selectimmune Pharma Ab | Therapeutic agent |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000169307A (ja) * | 1998-12-04 | 2000-06-20 | Yamagata Prefecture Technopolis Zaidan | 抗菌剤 |
JP2001515860A (ja) * | 1997-09-09 | 2001-09-25 | ラトガーズ ザ ステート ユニバーシティ オブ ニュージャージー | P型フィムブリエを有する細菌の表面への付着の阻害に有効な植物プロアントシアニジン抽出物 |
JP2001275604A (ja) * | 2000-04-04 | 2001-10-09 | Kikkoman Corp | 果汁粉末組成物及びその製造方法、並びに該果汁粉末組成物を含有させてなる健康食品 |
JP2002173424A (ja) * | 2000-12-04 | 2002-06-21 | Maruzen Pharmaceut Co Ltd | マトリックスメタロプロテアーゼ阻害剤 |
JP2004083581A (ja) * | 2002-07-02 | 2004-03-18 | Sanki Shoji Kk | 尿路感染症の治療剤 |
JP2005513125A (ja) * | 2001-12-20 | 2005-05-12 | シェーリング コーポレイション | 炎症性障害を治療する化合物 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4641151A (en) * | 1984-12-28 | 1987-02-03 | Victor Company Of Japan, Limited | Thermal transfer recording apparatus |
CN1088442A (zh) * | 1992-12-25 | 1994-06-29 | 李文旭 | 一种治疗肾炎药物的制取方法 |
CN1048173C (zh) * | 1994-08-11 | 2000-01-12 | 王志明 | 一种治疗性病的中药制剂及其制备方法 |
EP1486207A3 (en) * | 1996-01-23 | 2011-01-05 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
US6300514B1 (en) * | 1997-06-25 | 2001-10-09 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
AU3196200A (en) * | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Beta-amino acid derivatives |
EP1167346A4 (en) * | 1999-04-06 | 2003-07-23 | Ono Pharmaceutical Co | DERIVATIVES OF 4-AMINOBUTANIC ACID AND MEDICINES THAT CONTAIN THESE DERIVATIVES AS ACTIVE ACTIVE SUBSTANCES |
US6495578B1 (en) * | 1999-04-19 | 2002-12-17 | Shionogi & Co., Ltd. | Sulfonamide derivatives having oxadiazole rings |
DE60001654D1 (de) * | 1999-06-02 | 2003-04-17 | Oxford Natural Products Plc Co | Zubereitungen, welche preiselbeeren-frucht, dl-methionin und chinesische kräuter enthalten |
PL366201A1 (en) * | 2000-10-26 | 2005-01-24 | Pfizer Products Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
US20030108629A1 (en) * | 2001-07-17 | 2003-06-12 | Chou Wen Hsien | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
KR100456281B1 (ko) * | 2001-08-09 | 2004-11-09 | 마루젠세이야쿠 가부시키가이샤 | 방광기능개선제 또는 배뇨장애치료제, 및 방광기능개선용또는 배뇨장애치료용 음식물 |
JP4219810B2 (ja) * | 2001-10-26 | 2009-02-04 | 塩野義製薬株式会社 | Mmp阻害作用を有するスルホンアミド誘導体 |
GB0204159D0 (en) * | 2002-02-22 | 2002-04-10 | British Biotech Pharm | Metalloproteinase inhibitors |
KR100841901B1 (ko) | 2002-03-18 | 2008-06-27 | 동화약품공업주식회사 | 플라보노이드 계열 화합물 또는 이를 포함하는 강진향추출물을 함유한 매트릭스 메탈로프로테이나제 활성저해제 및 기능성 식품 |
JP2003342179A (ja) | 2002-05-24 | 2003-12-03 | Fancl Corp | 老化防止剤 |
WO2004014916A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
KR20030011731A (ko) | 2002-11-25 | 2003-02-11 | 미즈코리아 주식회사 | 항균 및 미용기능을 갖는 생약추출물과 이를 함유한 제품 |
US20050031718A1 (en) * | 2003-04-10 | 2005-02-10 | Pharmanex, Llc | Sea Buckthorn compositions and associated methods |
AU2003227952A1 (en) * | 2003-05-17 | 2004-12-03 | British Biotech Pharmaceuticals Ltd | Metalloproteinase inhibitors |
JP2005008539A (ja) | 2003-06-17 | 2005-01-13 | Fancl Corp | マトリックスメタロプロテイナーゼ阻害剤 |
WO2005019194A1 (en) * | 2003-08-23 | 2005-03-03 | Vernalis (Oxford) Limited | Derivatives of hydroxamic acid as metalloproteinase inhibitors |
WO2006028523A2 (en) * | 2004-04-29 | 2006-03-16 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
CN1593530A (zh) * | 2004-07-06 | 2005-03-16 | 谢子龙 | 三金分散片及其制备方法 |
CN100512866C (zh) * | 2004-08-13 | 2009-07-15 | 贵阳云岩西创药物科技开发有限公司 | 治疗泌尿系统等疾病的三金药物制剂及其制备方法 |
CN100360161C (zh) * | 2005-09-23 | 2008-01-09 | 徐忠慧 | 一种治疗糖尿病和肾炎的中药 |
US8153166B2 (en) | 2006-06-08 | 2012-04-10 | Chih-Hsiung Lin | Composition for prophylaxis or treatment of urinary system infection and method thereof |
TWI351965B (en) | 2006-06-09 | 2011-11-11 | Chih Hsiung Lin | Composition for prophylaxis or treatment of urinar |
-
2006
- 2006-06-08 US US11/422,924 patent/US8153166B2/en active Active
-
2007
- 2007-06-06 EP EP20070011162 patent/EP1880719A3/en not_active Withdrawn
- 2007-06-06 CA CA2590995A patent/CA2590995C/en active Active
- 2007-06-06 AU AU2007202584A patent/AU2007202584B2/en active Active
- 2007-06-07 CN CN2009101672518A patent/CN101670004B/zh not_active Expired - Fee Related
- 2007-06-07 CN CN2007101084292A patent/CN101084944B/zh not_active Expired - Fee Related
- 2007-06-07 JP JP2007152032A patent/JP4786598B2/ja active Active
-
2008
- 2008-06-12 HK HK08106526.2A patent/HK1111889A1/xx not_active IP Right Cessation
-
2009
- 2009-03-10 US US12/401,400 patent/US20090169653A1/en not_active Abandoned
-
2010
- 2010-09-13 HK HK10108658.4A patent/HK1142523A1/xx not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001515860A (ja) * | 1997-09-09 | 2001-09-25 | ラトガーズ ザ ステート ユニバーシティ オブ ニュージャージー | P型フィムブリエを有する細菌の表面への付着の阻害に有効な植物プロアントシアニジン抽出物 |
JP2000169307A (ja) * | 1998-12-04 | 2000-06-20 | Yamagata Prefecture Technopolis Zaidan | 抗菌剤 |
JP2001275604A (ja) * | 2000-04-04 | 2001-10-09 | Kikkoman Corp | 果汁粉末組成物及びその製造方法、並びに該果汁粉末組成物を含有させてなる健康食品 |
JP2002173424A (ja) * | 2000-12-04 | 2002-06-21 | Maruzen Pharmaceut Co Ltd | マトリックスメタロプロテアーゼ阻害剤 |
JP2005513125A (ja) * | 2001-12-20 | 2005-05-12 | シェーリング コーポレイション | 炎症性障害を治療する化合物 |
JP2004083581A (ja) * | 2002-07-02 | 2004-03-18 | Sanki Shoji Kk | 尿路感染症の治療剤 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021512855A (ja) * | 2018-02-05 | 2021-05-20 | ヴェットケアー オイ | ラクトバシラスを含む健康に有益な組成物及びその調製方法 |
WO2019188491A1 (ja) * | 2018-03-29 | 2019-10-03 | 森永乳業株式会社 | 抗老化用組成物 |
JPWO2019188491A1 (ja) * | 2018-03-29 | 2021-04-01 | 森永乳業株式会社 | 抗老化用組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP1880719A3 (en) | 2008-02-20 |
US8153166B2 (en) | 2012-04-10 |
US20080124405A1 (en) | 2008-05-29 |
CN101084944A (zh) | 2007-12-12 |
CN101670004A (zh) | 2010-03-17 |
CA2590995C (en) | 2015-07-21 |
CN101670004B (zh) | 2012-05-30 |
CA2590995A1 (en) | 2007-12-08 |
AU2007202584A1 (en) | 2008-01-03 |
HK1111889A1 (en) | 2008-08-22 |
AU2007202584B2 (en) | 2013-01-10 |
HK1142523A1 (en) | 2010-12-10 |
CN101084944B (zh) | 2010-08-25 |
EP1880719A2 (en) | 2008-01-23 |
JP4786598B2 (ja) | 2011-10-05 |
US20090169653A1 (en) | 2009-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4786598B2 (ja) | 泌尿系感染の予防又は治療に使用される組成物 | |
JP6685991B2 (ja) | 細菌バイオフィルムの処置および他の使用をはじめとする、生体医学的使用のための消毒薬としてのビスマス−チオール | |
Guay | An update on the role of nitrofurans in the management of urinary tract infections | |
JP6429131B2 (ja) | 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 | |
JP3425441B2 (ja) | 非炎症性及び非感染性腸障害の処置 | |
US20090191288A1 (en) | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | |
US9662360B2 (en) | Treatment of herpes, pseudomonas, staph, and hepatitis | |
WO2011041938A1 (zh) | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 | |
EP1112074B1 (en) | Taurolidine and/or taurultam against infectious ulcer or gastritis | |
BRPI0916885B1 (pt) | composição farmacêutica | |
LV13887B (lv) | Pretmikrobu līdzeklis | |
KR101296009B1 (ko) | 질 및 외음 감염의 예방 및/또는 치료 방법 | |
CA2973255A1 (en) | Methods of destroying and preventing bacterial and fungal biofilm by amino acid infusion | |
ES2734280T3 (es) | Composición farmacéutica para su uso en el tratamiento de infecciones de transmisión sexual | |
KR20200026118A (ko) | 헬리코박터 파일로리 제균용 조성물 | |
US8455021B2 (en) | Composition for prophylaxis or treatment of urinary system infection and method thereof | |
EP1646378B1 (en) | Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences | |
TWI351965B (en) | Composition for prophylaxis or treatment of urinar | |
CN107073018B (zh) | 尿路感染的治疗 | |
CN106974926B (zh) | 一种用于治疗压疮的药物组合物及其制备方法和用途 | |
TW200920392A (en) | Composition for prophylaxis or treatment of urinary system infection | |
Đorđević et al. | Protezni stomatitis-etiopatogeneza I terapijski pristup | |
AU2022443590A1 (en) | Compositions and methods for treatment of idiopathic pulmonary fibrosis | |
JPH0812576A (ja) | 抗ヘリコバクター・ピロリ剤 | |
Hobbs | Ototoxicity of netilmicin: Tjernstom O, Denneberg T, Harris S, et al. Acta Otolaryngol 94: 421, 1982 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101026 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110427 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110525 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110614 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110713 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4786598 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140722 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |